PsyBio Therapeutics Corp.
PSYBF · OTC
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.06 | -0.01 | 0.17 |
| FCF Yield | 13.25% | -5.47% | -10.03% | -6.73% |
| EV / EBITDA | -16.24 | -8.47 | -1.99 | -11.96 |
| Quality | ||||
| ROIC | 9.40% | 46.50% | 67.71% | 145.11% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -2.35 | 0.44 | 0.18 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 195.53% | -114.17% | 76.55% | 45.73% |
| Safety | ||||
| Net Debt / EBITDA | -0.51 | -0.04 | -0.15 | 0.01 |
| Interest Coverage | 0.00 | -210.56 | -213.71 | -169.92 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -4,989.57 | -2,953.49 | -1,080.19 | -785.47 |